Pages that link to "Q37735876"
Jump to navigation
Jump to search
The following pages link to Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome (Q37735876):
Displaying 50 items.
- Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome (Q21133920) (← links)
- The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome (Q33452721) (← links)
- Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating (Q33469255) (← links)
- Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis (Q33469703) (← links)
- Placebo effect in clinical trial design for irritable bowel syndrome (Q33586880) (← links)
- Placebo response: in studies on pain and under other clinical conditions (Q33938286) (← links)
- Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy (Q33958808) (← links)
- Recent advances in pharmacological treatment of irritable bowel syndrome (Q33958853) (← links)
- A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). (Q34106923) (← links)
- Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification (Q34241170) (← links)
- Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints (Q34309302) (← links)
- Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome (Q34323319) (← links)
- Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic (Q34645947) (← links)
- Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents (Q35018460) (← links)
- The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome: a meta-analysis of randomized, double-blind, placebo-controlled trials (Q35325063) (← links)
- Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine (Q35513153) (← links)
- Benefits from long-term treatment in irritable bowel syndrome (Q35681391) (← links)
- Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos (Q35784840) (← links)
- Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact (Q35962097) (← links)
- Low FODMAP diet (Q35970294) (← links)
- Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome (Q36166972) (← links)
- Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome (Q36345392) (← links)
- Probiotics for human health -new innovations and emerging trends (Q36531370) (← links)
- Drug development for the irritable bowel syndrome: current challenges and future perspectives (Q36579818) (← links)
- A novel biomarker panel for irritable bowel syndrome and the application in the general population (Q36970251) (← links)
- Effects of clonidine in women with fecal incontinence (Q37510329) (← links)
- The placebo response in clinical trials: more questions than answers (Q37876002) (← links)
- Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome (Q38175457) (← links)
- The use of non-narcotic pain medication in pediatric gastroenterology (Q38221358) (← links)
- Current and emerging pharmacotherapeutic options for irritable bowel syndrome (Q38254747) (← links)
- Emerging drug for diarrhea predominant irritable bowel syndrome (Q38366814) (← links)
- Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients (Q38367338) (← links)
- Placebo effects and their determinants in gastrointestinal disorders (Q38551120) (← links)
- Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial. (Q39155626) (← links)
- Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. (Q39172677) (← links)
- Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. (Q39261094) (← links)
- What techniques might be used to harness placebo effects in non-malignant pain? A literature review and survey to develop a taxonomy (Q39408152) (← links)
- The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity (Q39825139) (← links)
- Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs (Q40976092) (← links)
- Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial (Q42113397) (← links)
- Placebo by proxy (Q43001958) (← links)
- A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (Q43338955) (← links)
- Adverse events appear to unblind clinical trials in irritable bowel syndrome (Q43439726) (← links)
- Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. (Q47804431) (← links)
- Placebo effect in patients with irritable bowel syndrome (Q48828283) (← links)
- Stool as a treatment for IBS: more questions than answers? (Q50178483) (← links)
- Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. (Q52558812) (← links)
- The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence. (Q52677763) (← links)
- Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. (Q52814578) (← links)
- Efficacy of mesalazine in IBS. (Q52837356) (← links)